Catalyst Funds Management’s Novavax NVAX Stock Holding History

Catalyst Funds Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,400	Closed	-$309K	–	1512
2024 Q2	$309K	Buy	+24,400	New	+$245K	0.08%	158

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Catalyst Funds Management's NVAX Position: Q3 2024 in Review

Catalyst Funds Management sold out of Novavax (NVAX) in Q3 2024, closing a stake of 24,400 shares — an estimated $309K sold.

Catalyst Funds Management first reported a position in NVAX in Q2 2024 and held it in 1 quarter. The position peaked at $309K in Q2 2024. 237 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

Catalyst Funds Management reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
Catalyst Funds Management sold 24,400 Novavax shares in Q3 2024, an estimated $309K.
Catalyst Funds Management first reported a position in Novavax in Q2 2024 and held it in 1 quarter.
Catalyst Funds Management's Novavax position peaked at $309K in Q2 2024.
237 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.